Results 111 to 120 of about 22,551 (179)

Japanese intractable and rare dermatologic diseases: From the official skin-centered nanbyo core to an illustrative mechanism-based framework. [PDF]

Intractable Rare Dis Res
Han Y, Qin TG, Song P.
europepmc   +1 more source

Dapsone induced hemolysis and drop in saturation in normal glucose-6-phosphate dehydrogenase level patients - alarming presentation of poor man's drug: A series of 12 cases and review of literature. [PDF]

Indian J Pharmacol
Pradhan S, Dash G.
europepmc   +1 more source

CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease. [PDF]

Mol Ther Adv
Gross N, Jochimsen A, Dräger S, Theocharis T, Recke A, van Beek N, Schmidt-Jiménez LF, Krohn S, Klausz K, Bieber K, Ludwig RJ, Peipp M.   +11 more
europepmc   +1 more source

Disseminated Erythema and Vesicles on the Trunk and Extremities in a Teenager: A Quiz. [PDF]

Acta Derm Venereol
Zhao C, Wang H, Wang L.
europepmc   +1 more source

Incidence of P200 pemphigoid: A nationwide study. [PDF]

J Eur Acad Dermatol Venereol
Jouen F, Carrette M, Golinski ML, Maho-Vaillant M, Lefebvre A, Gillibert A, Joly P, Hébert V.   +7 more
europepmc   +1 more source

The Changing Trends in the Incidence and Clinical Presentation of Immunobullous Disorders Before and During the COVID-19 Era in a Tertiary Healthcare Centre in Andhra Pradesh. [PDF]

Cureus
Unnikrishnan P, Vijayashree J, Chintada D, Khatija Begum M, Gullipalli P, Chalamalasetty SS.   +5 more
europepmc   +1 more source

Cryptococcus neoformans Meningitis in a Patient With Epidermolysis Bullosa and Rheumatoid Arthritis. [PDF]

Cureus
Ng KL, Karunaratne KI.
europepmc   +1 more source

The treatment of bullous pemphigoid with topical roflumilast 0.3% cream case study. [PDF]

JAAD Case Rep
Domingues E.
europepmc   +1 more source

Tyrosine kinase signaling pathways as therapeutic targets in autoimmune subepidermal blistering skin diseases (pemphigoid diseases). [PDF]

Front Immunol
Vikár S, Mócsai A.
europepmc   +1 more source

Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab. [PDF]

JAAD Case Rep
Rasul T, Concilla A, Militello M, Torres P, Stepien A.   +4 more
europepmc   +1 more source